<DOC>
	<DOCNO>NCT01187199</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose combination bevacizumab ( Avastin ) temsirolimus ( Torisel ) give 1 3 study drug -- carboplatin ( Paraplatin ) , paclitaxel ( Taxol ) , sorafenib ( Nexavar ) . The safety drug combination also study .</brief_summary>
	<brief_title>Phase I Trial Bevacizumab Temsirolimus Combination With 1 ) Carboplatin , 2 ) Paclitaxel , 3 ) Sorafenib Treatment Advanced Cancer</brief_title>
	<detailed_description>The Study Drugs : Bevacizumab design prevent slow growth cancer cell block growth blood vessel . Temsirolimus design block growth cancer cell , may eventually cause cancer cell die . Carboplatin design damage DNA ( genetic material cell ) cancer cell , may eventually cause cancer cell die . Paclitaxel design damage DNA cancer cell , may eventually cause cancer cell die . Sorafenib design block function important protein cancer cell . These protein , active , part responsible abnormal growth behavior cancer cell . Study Drug Dose Level : If find eligible take part study , doctor decide study drug receive base disease type drug take past . Every participant receive bevacizumab temsirolimus . The study staff tell 3 drug ( carboplatin , paclitaxel , sorafenib ) receive . Once decide drug receive , assign dose level drug combination base join study . Three ( 3 ) 6 participant enrol dose level . The first group participant drug combination receive low dos . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose dose combination find . Your dose study drug may lower later , tolerate study drug combination well . Once high tolerate dose find group , 10 participant add group dose level . This call extension group . Study Drug Administration : Each cycle 21 day 28 day , depend study drug combination receive.If experience side effect , start next cycle may delay . Your doctor tell dose level assign . SORAFENIB ARM : If assign take sorafenib , take mouth 1 2 time every day ( study staff tell often take ) . You take sorafenib empty stomach , either 1 hour meal 2 hour meal . On Day 1 cycle , receive bevacizumab vein . The first infusion 90 minute . The next infusion may 60 minute first infusion well-tolerated . If tolerate second infusion well , third infusion may 30 minute . On Days 1 , 8 , 15 cycle , receive temsirolimus vein . During Day 1 Cycle 1 , receive 60 minute . If tolerate well Day 1 Cycle 1 , give 30 minute Days 8 15 Cycle 1 30 minute cycle , long still tolerate well . CARBOPLATIN ARM : If assign take carboplatin , receive vein 1 hour Day 1 cycle . On Day 1 cycle , receive bevacizumab vein . The first infusion 90 minute . The next infusion may 60 minute first infusion well-tolerated . If tolerate second infusion well , third infusion may 30 minute . On Days 1 , 8 , 15 cycle , receive temsirolimus vein . During Day 1 Cycle 1 , receive 60 minute . If tolerate well Day 1 Cycle 1 , give 30 minute Days 8 15 Cycle 1 30 minute cycle , long still tolerate well . PACLITAXEL ARM DOSE LEVELS 1-8 : If assign take paclitaxel Dose Levels 1 - 8 , receive vein 3 hour Days 1 , 8 , 15 cycle . On Day 1 cycle , receive bevacizumab vein . The first infusion 90 minute . The next infusion may 60 minute first infusion well-tolerated . If tolerate second infusion well , third infusion may 30 minute . On Days 1 , 8 , 15 cycle , receive temsirolimus vein . During Day 1 Cycle 1 , receive 60 minute . If tolerate well Day 1 Cycle 1 , give 30 minute Days 8 15 Cycle 1 30 minute cycle , long still tolerate well . PACLITAXEL ARM DOSE LEVELS 9 - 13 : If assign take paclitaxel Dose Levels 9 - 13 , receive paclitaxel vein 3 hour Days 1 , 8 , 15 cycle . On Days 1 15 cycle , receive bevacizumab vein . The first infusion 90 minute . The next infusion may 60 minute first infusion well-tolerated . If tolerate second infusion well , third infusion may 30 minute . On Days 1 , 8 , 15 , 22 cycle , receive temsirolimus vein . During Day 1 Cycle 1 , receive 60 minute . If tolerate well Day 1 Cycle 1 , give 30 minute Days 8 , 15 , 22 Cycle 1 30 minute cycle , long still tolerate well . Study Visits : During Cycle 1 : - Urine collect routine test Day 1 . - You physical exam , include measurement weight vital sign ( blood pressure , breathe rate , heart rate , temperature ) . - You ask well able perform normal activity daily live ( performance status ) Days 1 8 . - Blood ( 1 tablespoon ) drawn routine test Days 1 , 8 , 15 . On Day 1 Cycles 2 beyond : - You physical exam , include weight vital signs.. - Your performance status record . - Blood ( 1 tablespoon ) urine collect routine test After Cycle 2 , CT scan MRI scan check status disease every 2-3 cycle . After 6 month , may perform every 4 cycle doctor think best interest . Length Study : You may remain study long doctor think best interest . You take study disease get bad intolerable side effect occur . This investigational study . Bevacizumab , temsirolimus , carboplatin , paclitaxel , sorafenib commercially available . Bevacizumab FDA approve treatment colorectal cancer type lung cancer . Temsirolimus FDA approve treatment kidney cancer spread . Carboplatin FDA approve treatment ovarian cancer non-small cell lung cancer . Paclitaxel FDA approve ovarian , breast cancer , AIDS-related Kaposi 's sarcoma . It also approve combination cisplatin treatment ovarian non-small cell lung cancer . Sorafenib FDA approve treatment kidney cancer . The use drug together investigational . Up 278 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Inclusion : ( For treatment arm ) 2 . 1.1 Patients advanced metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy induces CR rate least 10 % improve survival least three month . 3 . 1.2 Patients must previous chemotherapy radiotherapy three week prior enter study . Six week require patient received therapy know delayed toxicity ( mitomycin nitrosurea ) . Five halflives require biologic/targeted therapy short ( &lt; 24 hour ) halflives pharmacodynamic effect . Patients may receive palliative radiation immediately ( ) treatment provide radiation target measurable evaluable disease . 4 . 1.3 Patients must measurable evaluable disease 5 . 1.4 ECOG performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % , Lansky &gt; /= 50 % ) . 6 . 1.5 Patients must normal organ function define : creatinine &lt; /= 1.5 x ULN child &lt; /= 2.0 x ULN adult ; total bilirubin &lt; /= 2.0 ; ALT ( SGPT ) /AST ( SGOT ) &lt; /= 5 X ULN . In patient significant liver disease chronically elevate liver transaminase , ALT/AST may elevate high 8 X ULN . 7 . 1.6 Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day last dose . 8 . 1.7 Ability understand willingness sign write informed consent document . 9 . 1.8 Life expectancy least 3 month . 10 . 1.9 Patients may receive experimental agent and/or concurrent anticancer agent therapy except hormonal maintenance . 11 . Inclusion : ( For carboplatin paclitaxel arm ) 12 . 2.1 Patients must normal marrow function define : absolute neutrophil count &gt; /= 1,500/mL ; platelet &gt; /= 100,000/mL . 13 . 2.2 Patient neuropathy CTC grade 1 less . 14 . Inclusion : ( For sorafenib arm ) 15 . 3.1 Patients must normal marrow function define : absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /= 75,000/mL . 1 . Exclusion : ( For treatment arm ) 2 . 4.1 Patients clinically significant unexplained bleeding within 28 day prior enter study . 3 . 4.2 Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg medication ) . 4 . 4.3 Patients clinically significant cardiovascular disease : History CVA within 6 month Myocardial infarction unstable angina within 6 month Unstable angina pectoris New York Heart Association Class &gt; II 5 . 4.4 Uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic Day 1 . 6 . 4.5 Pregnant lactate woman . 7 . 4.6 History hypersensitivity bevacizumab murine product , temsirolimus metabolite , component formulation . 8 . 4.7 Patients hemorrhagic brain metastasis . 9 . 4.8 Patients prior abdominal surgery within 30 day prior enter study . 10 . 4.9 Medications potent inducer inhibitor P450 3A4 avoid within 5 half life temsirolimus . 11 . Exclusion : ( For carboplatin treatment arm ) 12 . 5.1 Hypersensitivity carboplatin component formulation . 13 . Exclusion : ( For paclitaxel treatment arm ) 14 . 6.1 Hypersensitivity paclitaxel component formulation . 15 . Exclusion : ( For sorafenib treatment arm ) 16 . 7.1 History hypersensitivity sorafenib component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Avastin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Temsirolimus</keyword>
</DOC>